Chemo-immunotherapy before radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that has spread to nearby lymph nodes or the collarbone area, but not to distant organs like the liver or lungs.
- You are able to do your daily activities (ECOG performance status 0-1).
- Your blood counts and organ function (kidney, liver) are within certain healthy ranges.
- You have not had any prior treatment for this cancer, and you do not have other active cancers or serious illnesses like uncontrolled heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This trial looks at how best to add an immunotherapy “extra” before, during, and after standard chemoradiation for stage II–III esophageal squamous cell cancer that can’t be operated on. It may help reduce cancer that remains after treatment by targeting immune cells.
This trial tests an immunotherapy drug (adebrelimab) combined with chemotherapy before standard chemoradiation for people with locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.